Mycobacterial infections.
Infection due to Mycobacterium tuberculosis continues to plague humanity. In the United States, conditions have taken a decided turn for the worse, with an increasing frequency of infection and the spread of multiple-drug-resistant strains. A number of strategies are available to improve the management of this epidemic. Mycobacterium avium is now recognized as a significant cause of morbidity and mortality in patients with the acquired immunodeficiency syndrome. Therapy is limited due to relative drug resistance, drug intolerance, and drug malabsorption; however, potentially useful regimens are being developed.
Peloquin
C A
CA
Infectious Disease Pharmacokinetics Laboratory, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006801:Humans; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy* / Q000401:mortality; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D014481:United States / Q000453:epidemiology
D000995:Antitubercular Agents